Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 826 - 850 of 15098 in total
A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Approved
Matched Description: … A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment …
Matched Categories: … Alimentary Tract and Metabolism ... propantheline and psycholeptics …
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
Polistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate ... Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis ... Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … pathogenesis of CML and 15-30% of ALL cases. ... ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain. ... acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. Cetalkonium is approved by the FDA for its use...
Approved
Matched Description: … [A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and
Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued .
Approved
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Approved
Experimental
Matched Categories: … Blood and Blood Forming Organs …
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. ... Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development ... first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Karaya gum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Equipment and Supplies ... Alimentary Tract and Metabolism …
Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor ... [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also ... were treated with antihistamines, [rifampin], [ursodeoxycholic acid], [cholestyramine], [naltrexone], and
Matched Categories: … Bile and Liver Therapy ... Alimentary Tract and Metabolism …
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Approved
Investigational
Matched Description: … Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and
Matched Categories: … Nitrates and Nitrites ... Indicators and Reagents …
Approved
Experimental
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Approved
Investigational
Matched Description: … are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and
Matched Categories: … Decongestants and Antiallergics …
Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in...
Approved
Investigational
Matched Description: … [L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of ... depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and ... and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do …
Matched Categories: … Enzymes and Coenzymes …
Strontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. This kind of barrier protection for tooth hypersensitivity has, however, been...
Approved
Matched Description: … Strontium chloride (SrCl2) is a salt of strontium and chloride. ... protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and
Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Description: … the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and ... designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture …
Matched Categories: … meropenem and vaborbactam …
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … typically associated with a poorer prognosis (as compared to "classical" _EGFR_ mutants causing NSCLC) and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is...
Approved
Matched Description: … of myasthenia and as a fluorescent probe in HPLC. ... (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment …
Displaying drugs 826 - 850 of 15098 in total